BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31793190)

  • 21. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets.
    Aziz-Bose R; Monje M
    Curr Opin Oncol; 2019 Nov; 31(6):522-530. PubMed ID: 31464759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric diffuse intrinsic pontine glioma: where do we stand?
    Rashed WM; Maher E; Adel M; Saber O; Zaghloul MS
    Cancer Metastasis Rev; 2019 Dec; 38(4):759-770. PubMed ID: 31802357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Very Long-term Survivorship in Pediatric DIPG: Case Report and Review of the Literature.
    Dimentberg E; Marceau MP; Lachance A; Bergeron-Gravel S; Saikali S; Crevier L; Bourget C; Hawkins C; Jabado N; Giannakouros P; Renzi S; Larouche V
    J Pediatr Hematol Oncol; 2024 May; 46(4):211-215. PubMed ID: 38573000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
    Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
    Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas.
    Schramm K; Iskar M; Statz B; Jäger N; Haag D; Słabicki M; Pfister SM; Zapatka M; Gronych J; Jones DTW; Lichter P
    Neuro Oncol; 2019 Jul; 21(7):867-877. PubMed ID: 30943283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for paediatric brainstem gliomas.
    Khan DA; Laghari AA; Bari ME; Shamim MS
    J Pak Med Assoc; 2019 Sep; 69(9):1400-1402. PubMed ID: 31511736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
    Chastkofsky MI; Pituch KC; Katagi H; Zannikou M; Ilut L; Xiao T; Han Y; Sonabend AM; Curiel DT; Bonner ER; Nazarian J; Horbinski CM; James CD; Saratsis AM; Hashizume R; Lesniak MS; Balyasnikova IV
    Clin Cancer Res; 2021 Mar; 27(6):1766-1777. PubMed ID: 33272983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial.
    Izzuddeen Y; Gupta S; Haresh KP; Sharma D; Giridhar P; Rath GK
    J Neurooncol; 2020 Jan; 146(1):91-95. PubMed ID: 31728883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
    Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
    Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape.
    Panditharatna E; Yaeger K; Kilburn LB; Packer RJ; Nazarian J
    Cancer Genet; 2015; 208(7-8):367-73. PubMed ID: 26206682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
    Dalle Ore C; Coleman C; Gupta N; Mueller S
    Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective analysis on the consistency of MRI features with histological and molecular markers in diffuse intrinsic pontine glioma (DIPG).
    Giagnacovo M; Antonelli M; Biassoni V; Schiavello E; Warmuth-Metz M; Buttarelli FR; Modena P; Massimino M
    Childs Nerv Syst; 2020 Apr; 36(4):697-704. PubMed ID: 31848724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
    Su JM; Murray JC; McNall-Knapp RY; Bowers DC; Shah S; Adesina AM; Paulino AC; Jo E; Mo Q; Baxter PA; Blaney SM
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28283. PubMed ID: 32285998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.
    Larson JD; Kasper LH; Paugh BS; Jin H; Wu G; Kwon CH; Fan Y; Shaw TI; Silveira AB; Qu C; Xu R; Zhu X; Zhang J; Russell HR; Peters JL; Finkelstein D; Xu B; Lin T; Tinkle CL; Patay Z; Onar-Thomas A; Pounds SB; McKinnon PJ; Ellison DW; Zhang J; Baker SJ
    Cancer Cell; 2019 Jan; 35(1):140-155.e7. PubMed ID: 30595505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of multimodal
    Morana G; Tortora D; Bottoni G; Puntoni M; Piatelli G; Garibotto F; Barra S; Giannelli F; Cistaro A; Severino M; Verrico A; Milanaccio C; Massimino M; Garrè ML; Rossi A; Piccardo A
    Theranostics; 2020; 10(26):11881-11891. PubMed ID: 33204317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model.
    Haag D; Mack N; Benites Goncalves da Silva P; Statz B; Clark J; Tanabe K; Sharma T; Jäger N; Jones DTW; Kawauchi D; Wernig M; Pfister SM
    Cancer Cell; 2021 Mar; 39(3):407-422.e13. PubMed ID: 33545065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.